SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: Eli Lilly Campus in San Diego
Legal
Lilly Ups Legal Offensive Against Tirzepatide Copycats as FDA Mulls Shortage Status
Monday’s lawsuits from Eli Lilly are the first to be filed by the pharma since the regulator officially removed tirzepatide from its drug shortage database earlier this month.
October 22, 2024
 · 
2 min read
 · 
Tristan Manalac
An empty conference room overlooking a city
Business
Activist Investor Starboard Takes Aim at J&J Spinoff Kenvue on Heels of $1B Stake in Pfizer
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its rivals, according to The Wall Street Journal.
October 22, 2024
 · 
2 min read
 · 
Tristan Manalac
A team of research scientists in protective equipment working in a lab
Manufacturing
Radiopharma-Focused CDMO Nucleus Unveils Two New Plants, Looks to Create 100 Jobs
Nucleus RadioPharma’s two sites are meant to help address the industry’s lack of manufacturing and development capabilities, as well as geographic limitations associated with the short half-life of many radioactive components.
October 22, 2024
 · 
2 min read
 · 
Tristan Manalac
Employer Resources
Report: Employer Branding: What Matters to Life Sciences Candidates
October 22, 2024
 · 
1 min read
 · 
BioSpace Insights
Art collage, hands and falling coins in orange circle. Modern design of finance and business.
Funding
Seaport, Six Months Out of Stealth, Comes Back for $225M Raise
Seaport Therapeutics, kick started by the former leaders of Karuna Therapeutics, has raised $225 million in an oversubscribed Series B to fund a pipeline of neuropsychiatric medicines.
October 21, 2024
 · 
1 min read
 · 
Annalee Armstrong
Facade of Novo Nordisk's office in Fremont, California
GLP-1
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
October 21, 2024
 · 
1 min read
 · 
Heather McKenzie
Gentilly, France, March 21, 2021: Exterior view of the Sanofi headquarters building. Sanofi is a French multinational company specializing in the health sector
Deals
Sanofi Seals Deal With Private Equity Firm for 50% Stake in Consumer Healthcare Unit
Sanofi will sell a 50% controlling stake in consumer healthcare unit Opella to private equity firm CD&R, with the French government taking a stake as well to ensure the business remains in the county.
October 21, 2024
 · 
2 min read
 · 
Annalee Armstrong
FDA signage at its headquarters in Maryland
FDA
Lykos Announces ‘Productive’ Meeting With FDA Regarding Rejected MDMA Drug
In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next steps for the embattled program, following the FDA’s rejection in August 2024.
October 21, 2024
 · 
1 min read
 · 
Heather McKenzie
Entrance to Vertex's office in Boston, Massachusetts
Pain
Vertex Unveils Full Phase III Data for Non-Opioid Pain Candidate, Touts Safety Profile
BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental non-opioid pain medication “reaffirms our confidence in the strength of suzetrigine’s profile.” However, William Blair analysts view these data as “an incremental positive” as the company faces challenges in targeting the acute pain market.
October 21, 2024
 · 
3 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS